Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-IRDye800CW in Thyroid Cancer Surgery
NCT06095362Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab-IRDye800CW in thyroid carcinoma (TC), sponsored by University Medical Center Groningen. Primary endpoint: Tumor-to-Background Ratio. Started Nov 2021; status: completed.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
thyroid carcinoma (TC)
Beyond the preview
Go deeper on NCT06095362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06095362.